Vaxcyte, Inc. — Director's Dealing 2023

Dec 27, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2023-12-22

Reporting Person: PICKERING GRANT (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-22	Common Stock	M	9900	$2.03	Acquired	380814	Direct
2023-12-26	Common Stock	M	10000	$0.04	Acquired	390814	Direct
2023-12-26	Common Stock	S	7450	$61.323	Disposed	383364	Direct
2023-12-26	Common Stock	S	7550	$62.077	Disposed	375814	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-22	Stock Option (right to buy)	$2.03	M	9900	Disposed	2028-07-23	Common Stock (9900)	Direct
2023-12-26	Stock Option (right to buy)	$0.04	M	10000	Disposed	2025-04-23	Common Stock (10000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	152594	Indirect
Common Stock	152594	Indirect

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $60.885 to $61.76. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $61.96 to $62.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

F5: Shares are held directly by a trust for the benefit of the Reporting Person's son.

F6: Stock Option is fully vested and exercisable.